Screen · Berkshire Criteria

Buffett Quality Screen

Buffett's "wonderful business" criteria, quantified into six dimensions: earnings record (20), ROE quality (25 — Fortune's double standard), low leverage (15), pricing power (15), business stability (15) and capital efficiency (10), for a 0–100 total. The entry gate is the first of Berkshire's acquisition criteria — at least $50M average pre-tax earnings over the last three fiscal years (banks and insurers excluded, as leverage is their business model; investment trusts and closed-end funds excluded, as they are portfolios rather than operating companies). Recomputed periodically from each company's last ten fiscal years; cross-listings merged by canonical ticker. Hover the score for the six-dimension breakdown; companies we cover link to their report. Filtrado por market cap "Mega ≥$200B", profit streak "Full 10 yr", Has report: 7 match(borrar filtros).

# Activo Mkt Cap Score 10Y ROE Profit Streak Net Debt/Eq Gross Margin Informe FY
1 Arista Networks ANET · EE. UU. $227B
88/100 Excelente
24.1%low 15.3% 10 yr+ Net cash 64% Arista Networks: un estudio de largo plazo sobre el líder en conmutación de centros de datos23 de mayo de 2026 · Vigilar FY2025
2 Meta Platforms Inc. META · EE. UU. $1.4T
84/100 Excelente
24.3%low 17.3% 10 yr+ 0.0× 82% Meta Platforms: un estudio de inversión en valor profundo19 de mayo de 2026 · Vigilar FY2025
3 Taiwan Semiconductor Manufacturing TSM · EE. UU. $2.1T
82/100 Excelente
26.3%low 21.8% 10 yr+ Net cash 53% TSMC: un estudio en profundidad de inversión en valor22 de mayo de 2026 · Vigilar FY2025
4 Tencent Holdings Ltd 0700 · Hong Kong $548B
82/100 Excelente
21.1%low 13.2% 10 yr+ Net cash 48% Tencent Holdings: un estudio de investigación profundo28 de mayo de 2026 · Compra cautelosa FY2025
5 NVIDIA Corporation NVDA · EE. UU. $4.9T
81/100 Excelente
39.9%low 19.8% 10 yr+ Net cash 64% Memorando de inversión sobre NVIDIA22 de mayo de 2026 · Vigilar FY2026
6 AstraZeneca PLC AZN · EE. UU. $279B
64/100 Media
15.4%low 0.3% 10 yr+ 0.5× 78% AstraZeneca: un análisis en profundidad15 de junio de 2026 · Mantener FY2025
7 Contemporary Amperex Technology Co., Limite 3750 · Hong Kong $380B
62/100 Media
16.7%low 8.7% 10 yr+ Net cash 29% CATL: análisis profundo con el Zen Horizon Framework4 de junio de 2026 · Compra cautelosa FY2025

Data and methodology: the six dimensions quantify Berkshire's published acquisition criteria and Buffett's shareholder letters (1981/1987/1991/2007 among others). Qualitative tests in the originals (e.g. "simple, understandable business", "management in place") are out of scope, and price ("available at a fair price") is covered by each report's valuation range instead. Financials come from company annual reports (via EODHD); ratios are computed in reporting currency, the USD gate via static FX. "‡" marks companies whose equity is persistently negative or tiny (ROE falls back to ROCE); "†" marks missing gross profit (operating margin used). Investment trusts and closed-end funds are excluded on two tests — name and financial shape (operating margins beyond what an operating company can achieve); REITs and operating asset managers are unaffected. This is a quantitative first pass, not investment advice. When citing this data, please credit Zen Horizon (zh.app). See our methodology for the scoring process.